World Library  
Flag as Inappropriate
Email this Article

Fatty acid amide hydrolase

Article Id: WHEBN0007089667
Reproduction Date:

Title: Fatty acid amide hydrolase  
Author: World Heritage Encyclopedia
Language: English
Subject: Anandamide, Arachidonoyl serotonin, Endocannabinoid transporters, Kaempferol, Palmitoylethanolamide
Collection: Ec 3.5.1, Hydrolases Acting on Nonpeptide C-N Bonds, Integral Membrane Proteins
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Fatty acid amide hydrolase

Fatty acid amide hydrolase
Fatty acid amide hydrolase (FAAH) dimer shown with covalent inhibitor (MAFP, yellow) bound in the active site.
Identifiers
Symbol FAAH
Entrez 2166
HUGO 3553
OMIM 602935
PDB 1MT5
RefSeq NM_001441
UniProt O00519
Other data
EC number 3.5.1.99
Locus Chr. 1 p35-p34

Fatty acid amide hydrolase or FAAH (EC 3.5.1.99, oleamide hydrolase, anandamide amidohydrolase) is a member of the serine hydrolase family of enzymes. It was first shown to break down anandamide in 1993.[1] In humans, it is encoded by the gene FAAH.[2][3][4]

Contents

  • Function 1
  • Inhibitors and assays 2
  • Structure 3
  • See also 4
  • References 5
  • External links 6

Function

FAAH is an integral membrane hydrolase with a single N-terminal transmembrane domain. In vitro, FAAH has esterase and amidase activity.[5] In vivo, FAAH is the principal catabolic enzyme for a class of bioactive lipids called the fatty acid amides (FAAs). Members of the FAAs include:

FAAH knockout mice display highly elevated (>15-fold) levels of N-acylethanolamines and N-acyltaurines in various tissues. Because of their significantly elevated anandamide levels, FAAH KOs have an analgesic phenotype, showing reduced pain sensation in the hot plate test, the formalin test, and the tail flick test.[10] Finally, because of their impaired ability to degrade anandamide, FAAH KOs also display supersensitivity to exogenous anandamide, a cannabinoid receptor (CB) agonist.[6]

Due to the ability of FAAH to regulate nociception, it is currently viewed as an attractive drug target for the treatment of pain.

A mutation in FAAH has been linked to drug abuse and dependence.[11] Individuals with the mutation have higher levels of anandamide, the so-called "bliss" molecule, because of lower levels of FAAH, which may reduce anxiety and post-traumatic stress disorder.[12]

Inhibitors and assays

Both non-selective and selective inhibitors of the enzyme have been described. Examples of non-selective inhibitors include PMSF (phenylmethylsulfonylfluoride),[1] MAFP,[13][14] and ATMK (arachidonoyltrifluoromethylketone).[15] URB597 is a relatively selective, irreversible, carbamate-based inhibitor, though it also inhibits other serine hydrolases, such as carboxylesterases, in peripheral tissues.[16] Urea-based inhibitors such as PF-622 and PF-750 are more potent and more selective inhibitors of FAAH than URB597.[16]

The enzyme is typically assayed making use of a radiolabelled anandamide substrate, which generates free labelled ethanolamine, although alternative LC-MS methods have also been described.

Structure

The first crystal structure of FAAH was published in 2002 (PDB ID: 1mt5).[4] Structures of FAAH with drug-like ligands were first reported in 2008, and include covalent (e.g. 2vya, 2wap, 2wj1, 3qkv) and non-covalent (e.g. 3qj9, 4do3) inhibitors.

See also

References

  1. ^ a b Deutsch DG, Chin SA (Sep 1993). "Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist". Biochemical Pharmacology 46 (5): 791–6.  
  2. ^ Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (Nov 1996). "Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides". Nature 384 (6604): 83–7.  
  3. ^ Giang DK, Cravatt BF (Mar 1997). "Molecular characterization of human and mouse fatty acid amide hydrolases". Proceedings of the National Academy of Sciences of the United States of America 94 (6): 2238–42.  
  4. ^ a b Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF (Nov 2002). "Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling". Science 298 (5599): 1793–6.  
  5. ^ Patricelli MP, Cravatt BF (Oct 1999). "Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism". Biochemistry 38 (43): 14125–30.  
  6. ^ a b Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH (Jul 2001). "Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase". Proceedings of the National Academy of Sciences of the United States of America 98 (16): 9371–6.  
  7. ^ Saghatelian A, Trauger SA, Want EJ, Hawkins EG, Siuzdak G, Cravatt BF (Nov 2004). "Assignment of endogenous substrates to enzymes by global metabolite profiling". Biochemistry 43 (45): 14332–9.  
  8. ^ Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA (Jun 1995). "Chemical characterization of a family of brain lipids that induce sleep". Science 268 (5216): 1506–9.  
  9. ^ Saghatelian A, McKinney MK, Bandell M, Patapoutian A, Cravatt BF (Aug 2006). "A FAAH-regulated class of N-acyl taurines that activates TRP ion channels". Biochemistry 45 (30): 9007–15.  
  10. ^ Cravatt BF, Lichtman AH (Oct 2004). "The endogenous cannabinoid system and its role in nociceptive behavior". Journal of Neurobiology 61 (1): 149–60.  
  11. ^ Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF (Jun 2002). "A missense mutation in human fatty acid amide hydrolase associated with problem drug use". Proceedings of the National Academy of Sciences of the United States of America 99 (12): 8394–9.  
  12. ^ "The Feel-Good Gene". New York Times. 6 March 2015. Retrieved 9 March 2015. 
  13. ^ Deutsch DG, Omeir R, Arreaza G, Salehani D, Prestwich GD, Huang Z, Howlett A (Feb 1997). "Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase". Biochemical Pharmacology 53 (3): 255–60.  
  14. ^ De Petrocellis L, Melck D, Ueda N, Maurelli S, Kurahashi Y, Yamamoto S, Marino G, Di Marzo V (Feb 1997). "Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase". Biochemical and Biophysical Research Communications 231 (1): 82–8.  
  15. ^ Koutek B, Prestwich GD, Howlett AC, Chin SA, Salehani D, Akhavan N, Deutsch DG (Sep 1994). "Inhibitors of arachidonoyl ethanolamide hydrolysis". The Journal of Biological Chemistry 269 (37): 22937–40.  
  16. ^ a b Ahn K, Johnson DS, Fitzgerald LR, Liimatta M, Arendse A, Stevenson T, Lund ET, Nugent RA, Nomanbhoy TK, Alexander JP, Cravatt BF (Nov 2007). "Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity". Biochemistry 46 (45): 13019–30.  

External links

  • fatty-acid amide hydrolase at the US National Library of Medicine Medical Subject Headings (MeSH)
  • Proteopedia FAAH entry - interactive structure (JMOL) of inhibitor-bound FAAH
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.